Ai Drug Discovery

Burlington, Mass. – October 30, 2026 -- Azenta (Nasdaq: AZTA) has secured an exclusive license to Elegen Corp.'s cell-free DNA synthesis platform and acquired SynPlexity Inc., two moves aimed at expanding the gene synthesis and discovery capabilities of its GENEWIZ business.

Elegen license adds cell-free DNA manufacturing to the GENEWIZ portfolio

The Elegen platform is designed to improve DNA quality, delivery speed and manufacturing scalability. It supplies sequence-verified DNA constructs and templates that simplify preparation for downstream experiments, including antibody discovery.

Production workflows are compact, so regional capacity can be added close to customers as demand requires.

Beijing – October 14, 2026 -- Likang Life Sciences, whose lead cancer vaccine candidate LK101 holds clinical trial authorization from China's NMPA (2023) and U.S. FDA IND clearance (2025), will sponsor and exhibit at the Abu Dhabi Future Health Summit 2026 on October 20–22 at the ADNEC Centre.

Likang co-founder joins October 21 oncology panel

Shannon Cheung, Co-Founder and Vice Chairman of Likang, will speak on the panel "The Future of Cancer" on October 21. The session will cover precision oncology and the translation of innovative cancer treatments into clinical practice. It forms part of the summit's Abu Dhabi Blueprints series and will examine the roles of research, investment, policy, and international collaboration in getting new therapies to patients.

Boston – September 15, 2026 -- EMD Serono, Inc., the U.S. and Canada healthcare business of Merck KGaA, Darmstadt, Germany, has acquired two preclinical fertility drug programs from PostEra, a biotechnology company that uses artificial intelligence for small-molecule drug discovery.

EMD Serono takes over two AI-derived fertility programs from PostEra

The deal covers a class of follicle-stimulating hormone receptor (FSHR) agonists for ovarian stimulation in IVF and a separate class of luteinizing hormone/chorionic gonadotropin receptor (LHCGR) agonists targeting male infertility and ovulation triggering in IVF. Both programs were developed over the past two years using PostEra's Proton AI platform and remain in preclinical development, with safety and efficacy in humans not yet established.